Virology Market

Virology Market Forecast and Outlook 2026 to 2036

The global virology sector is on track to achieve a valuation of USD 4.0 billion by 2036, accelerating from USD 2.4 billion in 2026 at a CAGR of 5.0%. As per Future Market Insights, expansion is structurally underpinned by the global imperative to maintain pandemic preparedness infrastructure, the rising prevalence of dengue and respiratory viruses, and the transition from reactive diagnosis to proactive viral surveillance through centralised digital pathogen networks. The World Health Organization (WHO) reported in its 2024 Global Hepatitis Report that viral hepatitis causes 1.3 million deaths annually, validating the persistent disease burden that sustains diagnostic and therapeutic virology investment. This mortality burden compels governments to invest in expanded testing infrastructure and long-acting injectable prevention programmes. Simultaneously the regulatory landscape is advancing as the FDA and EMA approve long-acting injectable antivirals and rapid point-of-care diagnostics which forces traditional virology reagent suppliers to integrate into broader diagnostic platform ecosystems.

In September 2025, Gilead Sciences partnered with PEPFAR to deliver lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor, for pre-exposure prophylaxis in up to two million people in low and lower-middle income countries. FMI is of the opinion that long-acting injectable antivirals for prevention will capture 15 to 20% of the global HIV PrEP market by 2030, driven by superior adherence rates compared to daily oral regimens and the PEPFAR distribution infrastructure that enables population-scale deployment.

The competitive landscape in 2025 and 2026 is defined by long-acting therapeutic launches and diagnostic platform expansion. ViiV Healthcare (GSK) secured NICE recommendation in October 2025 for cabotegravir for PrEP, the first long-acting HIV prevention option reimbursed in England and Wales. Enanta Pharmaceuticals reported positive Phase 2b data for zelicapavir (EDP-938) for RSV treatment in high-risk adults in September 2025. Roche Diagnostics received EU CE mark in January 2026 for its Elecsys Dengue Ag test and cobas BV/CV assay. Lonza signed a definitive agreement in November 2025 to acquire Redberry SAS for rapid microbiology testing using solid-phase cytometry. Australia is scheduled to roll out a nationwide pathogen network by March 2026 for real-time viral surveillance. As per FMI, this convergence of long-acting injectable prevention, rapid decentralised diagnostics, and nationwide pathogen surveillance networks confirms that virology is transitioning from a reactive diagnostic discipline into a continuous population health management platform.

Summary of Virology Market

What Is Growth Outlook for Virology Market as per Future Market Insights Projection?

Future Market Insights projects the virology industry to expand at a CAGR of 5.0% from 2026 to 2036, increasing from USD 2.4 Billion in 2026 to USD 4.0 Billion by 2036.

FMI Research Approach: FMI proprietary forecasting model based on WHO Global Hepatitis Report mortality data, HIV PrEP prescription volumes, and viral diagnostic test consumption tracking.

How Do FMI Analysts Perceive Virology Market to Evolve?

FMI analysts perceive the market evolving toward integrated virology platforms combining long-acting injectable prevention, rapid molecular diagnostics, and at-home self-collection kits connected to centralised digital pathogen surveillance networks.

FMI Research Approach: Gilead-PEPFAR partnership analysis and Australia nationwide pathogen network rollout tracking.

Which Country Holds Largest Share in Global Virology Market?

The United States holds a significant share of the global virology market by value which is supported by the FDA's active antiviral drug approval pipeline, the scale of its HIV prevention programmes, and the concentration of virology diagnostic manufacturers.

FMI Research Approach: FMI country-level revenue modeling by HIV PrEP prescription data and virology diagnostic reagent procurement volumes.

How Large Will Virology Market Be by 2036?

The global virology market is projected to reach USD 4.0 Billion by 2036.

FMI Research Approach: FMI long-term revenue forecast derived from WHO viral disease burden projections and pandemic preparedness investment tracking.

What Is Definition of Virology Market?

The virology market includes diagnostic reagents, molecular testing platforms, rapid antigen tests, self-collection kits, antiviral therapeutics, and viral surveillance systems used to detect, diagnose, treat, and monitor viral infections across clinical, public health, and pharmaceutical settings.

FMI Research Approach: FMI market taxonomy aligned with WHO ICD-11 viral disease classification and FDA antiviral drug approval categories.

What Are Globally Unique Trends Shaping Virology Market?

Globally unique trends include twice-yearly injectable HIV PrEP deployment at scale (Gilead lenacapavir with PEPFAR), at-home self-collection kits with built-in stabilising reagents, and nationwide real-time pathogen surveillance networks (Australia 2026).

FMI Research Approach: Gilead-PEPFAR partnership and Australia pathogen network rollout analysis.

Virology Market Key Takeaways

Metric	Details
Industry Size (2026)	USD 2.4 Billion
Industry Value (2036)	USD 4.0 Billion
CAGR (2026 to 2036)	5.0%

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

Key Industry Highlights

Strategic Collaboration among Pharmaceutical Companies and Research Institutes Anticipates the Growth of the Market

Strategic collaborations among pharmaceutical companies and research institutes are crucial for the acceleration of the growth of the virology market. These collaboration aid them to combine expertise in drug development, and innovation in clinical research. This way, pharmaceutical companies are able to use knowledge and advanced technologies of academic and research institutions in finding novel antiviral compounds, understanding viral mechanisms, and optimizing drug formulations.

Other advantages of such partnerships include the opportunity to share scientific data and clinical trials, allowing for better understanding of regulatory procedures and ensuring safe and effective development of new treatments

These partnerships also make it possible for access to expert infrastructure, which includes high-performance laboratories and throughput screening platforms that speed up discovery. Besides that, research centers advance cutting-edge knowledge in areas such as virology, immunology, and genomics and facilitate innovation.

For instance, in February 2023, GSK plc, invested USD 1.5 million in University of Alberta Li Ka Shing Institute of Virology (LKSIoV). The investments are aimed to fund the quest for breakthroughs in antivirals, and vaccines.

Growing Emphasis of Research Institutes towards Development of Diagnostic Tools with Expanded Applications

Research institutes mainly focus on advanced diagnostic tools that identify diseases at an early stage and provide more accurate, quick, and cost-effective results. This extends the possibilities of diagnostics, from general diseases up to very rare cases of genetic ones, and significantly extends the circle of possible clients.

These advances also ease the burden on healthcare systems by facilitating personalized medicine. As diagnostic tools become more specific, health professionals can individualize treatments, which enhances treatment efficacy and minimizes adverse effects. Research into diagnostic tools that have wider applications, such as point-of-care settings or in remote areas, further improves accessibility and leads to better global health outcomes.

The effect of all these changes is a more dynamic, accessible, and diversified market, which attracts investments and creates continuous improvements in diagnostic technologies. For instance, in 2022, Columbia University received approval for the use VirCapSeq in New York State in the United States. This VirCapSeq, can be used for the diagnosis of systemic and respiratory tract infections.

Therefore, growing advancements and the efforts put down by research institutes eventually mark a shift toward broad, versatile diagnostic tools that aid in transforming healthcare delivery which fuels the overall growth of the diagnostic segment in virology market.

The Development of mRNA vaccines for Several Infectious Diseases Presents Significant Growth Opportunities for Manufacturers

mRNA technology has proved extremely effective in the rapid generation of vaccines. This technology allows manufacturers to rapidly adapt and respond to emerging infectious threats, making it an attractive platform for addressing several diseases such as influenza, Zika, and HIV, to viral infections like HPV.

Another important advantage is the scalability of mRNA production. Unlike traditional vaccines, which often require growing the virus in labs or cultivating in eggs, mRNA vaccines can be synthesized in large quantities much more quickly and cost-effectively. This enables manufacturers to meet global demands efficiently, especially in low-resource settings.

In addition, mRNA technology allows the development of vaccines against a number of variants or strains of a virus, which also dispels questions of mutation and resistance. With the increased demand for rapid, and adaptable vaccines, manufacturers with mRNA capabilities have considerable competitive advantages in the virology market. These added advantages allows companies with mRNA vaccine technologies to pose significant growth in both established and emerging market.

High Development and Production Costs Associated with Virology Research for the Development of Vaccines and Other related products hinder Market Growth

Research and development of virology based vaccines and therapies require huge investments and advanced technologies, along with large number of clinical trials, and infrastructure. Such a process for developing the vaccines, using methods like mRNA-based or viral vector vaccines, requires huge scientific research that would take several years and lot of investment. Some costs may eventually dissuade the small biotech firms from stepping into the markets and slowing the innovation in these sectors.

The high costs associated with specialized facilities and expertise in the manufacturing process hinders its further market reach. This makes rapid scaling of production challenging, especially when there is an emerging viral threat.

This cost burden normally falls on the consumer or governments, leading to a lack of access, especially within low- and middle-income countries. In this way, even when efficient products are developed, ultimately their affordability and accessibility hamper the global adoption processes. These financial hindrances ultimately serve to limit the overall market reach by delaying widescale distributions and stalling the overall progress of the growth of the virology market.

2021 to 2025 Global Virology Drugs Sales Outlook Compared to Demand Forecast from 2026 to 2036

The applications of virology in the areas of vaccine development, such as antiviral therapies, and diagnostic technologies have emerged as a technological forefront. The above mentioned applications highly contribute to the public health by preventing and curing viral infections.

A number of factors such as vaccine development for smallpox and polio, increase in integration of studies in virology for drug development, and growing adoption of anti-viral drugs to meet the rising prevalence of HIV/AIDS, anticipates the growth of the virology research.

Moreover, initiatives made by research institutes and pharmaceutical companies in the current gene-editing technologies like CRISPR and next-generation sequencing further propels the market growth. With time, next-generation sequencing has become better in identifying the viral mutation and outbreaks.

Growth in the future of the virology market is driven by innovations in vaccine platforms, gene therapies, antiviral drugs, and real-time diagnostics. Increasing focus of the government of several countries on preparedness for pandemic conditions, increasing advancements in mRNA technology along with growing focus of manufacturer on the development of immune-based therapies contribute to the growth of the virology market.

Market Concentration

Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 61.6% in global market. These market leaders are characterized by high production capacity and a wide product portfolio. These market leaders are distinguished by their extensive expertise in manufacturing and reconditioning across multiple packaging formats and a broad geographical reach, underpinned by a robust consumer base. Prominent companies within tier 1 include Gilead Sciences, Inc., AbbVie and GSK plc

Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 24.4% market share. These are characterized by a strong presence overseas and strong market knowledge. These market players have good manufacturing technology and ensure regulatory compliance but may not have access to global reach. Prominent companies in tier 2 include Amarna Therapeutics, Theolytics and Nektar Therapeutics

Finally, Tier 3 companies, act as a suppliers to the established market players. They are essential for the market as they specialize in specific products and cater to niche markets, adding diversity to the industry.

Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the virology market remains dynamic and competitive.

Country-wise Insights

The section below covers the industry analysis for the virology market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with a value share of 84.7% through 2036. In Asia Pacific, South Korea is projected to witness a CAGR of 5.4% by 2036

Countries	Value CAGR (2026 to 2036)
UK	4.4%
China	4.2%
Japan	4.6%
South Korea	5.2%
Germany	5.1%
India	3.8%
GCC Countries	2.4%

Growing Investment of Private Organizations and Pharmaceutical Companies in Virology Research Contributes to the Growth of the Market in United States

United States virology market is poised to exhibit a CAGR of 6.6% between 2026 and 2036. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.

Key factors driving the market of virology in the US include increasing investment from private organizations and pharmaceutical companies in the field. These investments lead to advanced antiviral therapies, vaccines, and diagnosis technologies to tackle emerging and established viral threats. Private organizations, especially the biotech companies, are highly innovative-which constantly focuses on new frontiers of drug discovery, and development of new vaccine platforms.

In addition, pharmaceutical companies in United States are also emphasizing on expanding their portfolios related to antiviral drugs and vaccines due to increasing demand. This, in turn, is improving technological progress, enhancing healthcare solutions, and ensuring a continuous pipeline of antiviral products, thereby helping increase investment in virology research which contribute to the overall growth of the virology market in the United States

Emerging and Re-emerging Viral Infections Anticipate the Growth of Market in China

China is anticipated to grow at a CAGR of 4.2% and is anticipated to grow at a substantial CAGR throughout the forecast period.

The growth of the virology market in China is greatly contributed to by emerging and re-emerging viral infections, which raise the demand for vaccines, antiviral treatments, and diagnostic solutions. China is suffering from new viral menaces, such as the recent COVID-19 pandemic, but also from diseases that have been a concern for some time, like influenza, hepatitis, and avian influenza.

The need for rapid detection, effective vaccines, and antiviral drugs to manage these outbreaks propels the market for further growth. Additionally, the heavy population and urbanization of China increase the chances of transmission of viruses, boosting demand for healthcare products related to virology. Increased research, government funding, and international collaboration with health organizations, accelerate innovation in virology, making it one of the major drivers of growth within the country's healthcare market.

The Support and Funding Extended by the German Government Anticipate the Growth of the Virology Market

Germany is expected to have a strong foothold in the virology market. In 2024 the country is projected to account for substantial share of the virology market. Investment plans made by government by Germany for research and development of vaccines and drugs that are more into prevention of viral diseases majorly anticipate the growth of the market.

For instance, in July 2023, The German Federal Ministry of Education and Research (BMBF) approved funding for five non-profit organizations through KfW. The aim of this funding is to focus on R&D of affordable and accessible vaccines for neglected population. Also, vaccination programs, and the preparedness of the government to handle emerging viral threats through various government-supported public health initiatives, are other factors that increase the demand in the market.

Investments in virology research by the German government, and promoting academic-private collaborations, accelerates solutions to ensure continuous growth in the virology market for the improvement of public health. Therefore, the government support and funding, especially by the government of Germany, is one of the key factors that is subjected to boost the growth of the virology market, as it enhances research, development, and innovation in the field.

Category-wise Insights

The section contains information about the leading segments in the industry. By product type, diagnostic segment hold highest share of the market.

Diagnostic Test Segment Dominate the Virology Market in terms of Value owing to its Ability to Early Detect and Monitor Viral Infections

Product Type	Diagnostic Test
Value Share (2026)	46.4%

Diagnostic testing is the leading segment in the virology market because of the high importance that it plays in early detection, monitoring, and managing viral infections. Accurate diagnosis and speed form very vital constituents of treatment in outbreaks and pandemics. Growing upsurge of viral diseases such as COVID-19, HIV, and influenza, PCR tests, increase in number of centers conducting antigen tests, growing adoption of next-generation sequencing techniques anticipates the growth of the market.

Early diagnosis allows for timely intervention, improving patient outcomes and helping to contain the spread of infections. Besides, new developments in molecular diagnostics, point-of-care testing, and automation raise accuracy and speed, thereby driving the market further. While viral infections continue to pose a threat to public health, the segment of diagnostic tests plays an indispensable role in virology, both for healthcare providers and public health initiatives.

Availability of Advanced Diagnostic Facilities and Skilled Healthcare Professionals aid Hospitals to hold Dominant Position in Virology Market

End User	Hospitals
Value Share (2026)	58.4%

The hospitals segment is forecast to account for a share of 58.4% and is poised to expand at a substantial CAGR during the forecast period.

Hospitals are major healthcare facilities that are generally visited by patients in severe or complicated viral infections. They are well facilitated with advanced diagnostic tools and skilled healthcare professionals who can handle critical cases. Besides this, hospitals also act as a major hub for the management of viral diseases, which includes inpatient admission, surgical procedures, and anti-viral therapies.

Though clinics, laboratories, and diagnostic centers are indispensible to the diagnosis and treatment processes, it is the hospitals that dominate by virtue of sheer volume of patients treated and services provided in advanced diagnostics and comprehensive treatment for viral infections.

Competitive Landscape

Substantial investments and focus is seen in the virology industry towards launch of new series of products to the market. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence. In addition, many of the key players are also emphasizing on making strategic investments for accelerating development of their pipeline products.

Recent Developments

• In September 2025, Gilead Sciences partnered with PEPFAR to deliver lenacapavir, its twice-yearly injectable HIV PrEP, to up to two million people in low and lower-middle income countries.
• In January 2026, Roche Diagnostics received EU CE mark for its Elecsys Dengue Ag test and cobas BV/CV assay for improved diagnostic accuracy.
• In November 2025, Lonza signed a definitive agreement to acquire Redberry SAS for rapid microbiology testing using solid-phase cytometry to strengthen biopharmaceutical QC capabilities.

Key Players of Virology Drugs Industry

• Tevogen Bio
• Pfizer
• VerImmune Inc
• Takeda Pharmaceuticals
• AbbVie
• Virogin Biotech Limited
• Kineta
• Gilead Sciences, Inc.
• Amarna Therapeutics
• Dewpoint Therapeutics
• ARS Pharmaceuticals
• Abivax
• Theolytics
• Nektar Therapeutics
• GSK plc

Market Definition

The virology market represents revenue generated from diagnostic, therapeutic, and surveillance products and services for viral infections. The market measures the value of molecular PCR assays, rapid antigen tests, self-collection kits, antiviral drugs, long-acting injectable preventatives, and pathogen surveillance platforms sold to hospitals, public health agencies, and pharmaceutical companies.

Inclusions cover molecular virology diagnostic reagents (PCR, RT-PCR), rapid antigen and antibody tests, at-home self-collection kits with stabilising reagents, antiviral therapeutics (oral and injectable), long-acting injectable PrEP (lenacapavir, cabotegravir), viral load monitoring assays, and digital pathogen surveillance platforms. Dengue, HIV, RSV, hepatitis, and influenza diagnostics are included.

Exclusions include vaccine manufacturing revenue (covered separately), general bacteriology diagnostics without virology focus, hospital infection control consumables, and pharmaceutical drug discovery R&D costs prior to clinical trial stage.

Scope of Report

Items	Values
Quantitative Units (2026)	USD 2.4 Billion
Product Type	Molecular PCR Assays, Rapid Antigen Tests, Self-Collection Kits, Antiviral Therapeutics, Long-Acting Injectable PrEP, Pathogen Surveillance Platforms
Application	HIV, Hepatitis, RSV, Dengue, Influenza, Emerging Pathogens
End User	Hospitals, Public Health Laboratories, Pharmaceutical Companies, At-Home Testing
Regions Covered	North America, Europe, Asia Pacific, Latin America, Africa
Countries Covered	USA, UK, Germany, Australia, India, Japan, and 40+ countries
Key Companies Profiled	Gilead Sciences, ViiV Healthcare (GSK), Roche Diagnostics, Lonza, Enanta Pharmaceuticals

Key Segments of Virology Industry

By Product Type:

In terms of product type, the industry is divided into diagnostic tests, viral infection controlling methods, antiviral chemotherapy and interferons

By Application:

In terms of application, the industry is segregated into skin and soft tissue infections, respiratory tract infections, GI tract infections, urinary tract infections, eye infections, CNS infections, sexually transmitted diseases and perinatal infections

By End User:

The industry is classified by end user as hospitals, clinics, laboratories, diagnostic centres, blood banks and pharmacies

By Region:

Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa (MEA) have been covered in the report.

Bibliography

• World Health Organization. (2024). Global Hepatitis Report 2024: 1.3 Million Annual Deaths from Viral Hepatitis. WHO.
• Gilead Sciences. (2025, September). Gilead and PEPFAR partnership for lenacapavir HIV PrEP delivery. Gilead Newsroom.
• Roche Diagnostics. (2026, January). EU CE mark for Elecsys Dengue Ag test and cobas BV/CV assay. Roche Investor Relations.
• ViiV Healthcare. (2025, October). NICE recommendation for cabotegravir PrEP in England and Wales. ViiV Healthcare Newsroom.